The association between (nucleotide binding oligomerisation domain containing 2) gene polymorphisms and susceptibility to sarcoidosis have been extensively investigated in recent years. However, the results from previous studies remain controversial. To assess the association of polymorphisms and sarcoidosis susceptibility, we performed a meta-analysis. PubMed, Embase, CNKI and Wanfang databases were examined for all relevant studies up until 8 October 2016. In all, 968 cases and 1549 controls in eight case-control studies were included which mainly consisted of Caucasian participants. The relevant data were extracted and the odds ratio (OR) with 95% confidence intervals (95% CI) calculated to assess the strength of any associations. Statistical analyses were calculated using STATA12.0 software and Revman5.3 software. The associations between SNP rs2066844, rs2066845, rs2066847, rs1861759 polymorphisms and the risk of sarcoidosis were evaluated in allelic, dominant, recessive and additive models. The pooled data showed that the rs2066845 polymorphism was associated with sarcoidosis susceptibility in allelic model (C vs. G, OR=1.86, 95% CI: 1.14-3.04, P=0.01), dominant model (GC + CC vs. GG, OR=1.84, 95% CI: 1.11-3.05, P=0.02) and additive model (GC vs. GG, OR=1.79, 95% CI: 1.08-2.97, P=0.02). However, the results suggested that the rs2066844, rs2066847 and rs1861759 polymorphisms might not be associated with a risk of sarcoidosis. This meta-analysis indicated that the 'C' allele of SNP rs2066845 may be a risk factor for sarcoidosis, especially in Caucasians, whilst rs2066844, rs2066847 and rs1861759 may not be associated with a risk of developing sarcoidosis. .
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170086 | PMC |
| http://dx.doi.org/10.36141/svdld.v35i2.6257 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mendelian randomization analysis reveals causal effects of inflammatory bowel disease and autoimmune hyperthyroidism on diffuse large B-cell lymphoma risk.
Sci Rep
November 2024
Key Laboratory of Integrated Traditional Chinese and Western Medicine for Hematology, Health Commission of Shandong Province; Institute of Hematology, Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China.
Article Synopsis
- This study investigates the controversial link between autoimmune diseases (ADs) and the risk of developing diffuse large B-cell lymphoma (DLBCL) using Mendelian randomization methods.
- Researchers analyzed data from nine ADs and compared it with DLBCL cases, aiming to establish causal associations using genetic markers (SNPs).
- The findings indicated that inflammatory bowel disease and autoimmune hyperthyroidism significantly increase DLBCL risk, while other conditions like asthma and psoriasis showed no significant associations.
Autoimmune Diseases and Risk of Non-Hodgkin Lymphoma: A Mendelian Randomisation Study.
Cancer Med
November 2024
Yale Center for Perinatal, Pediatric, and Environmental Epidemiology, Yale School of Public Health, New Haven, Connecticut, USA.
Article Synopsis
- Non-Hodgkin lymphoma (NHL) is a prevalent type of blood cancer, and its causes remain largely unknown, though autoimmune diseases are suspected as potential risk factors.
- A study used Mendelian randomization to investigate the relationship between ten autoimmune diseases and NHL risk, utilizing data from various European ancestry cohorts.
- The results indicated that genetically predicted susceptibility to type 1 diabetes and sarcoidosis may lower NHL risk, while no significant association was found for the other eight autoimmune diseases; further research is needed to confirm these findings.
Contemporary Concise Review 2023: Interstitial lung disease.
Respirology
December 2024
School of Medicine, University of Western Australia, Crawley, Western Australia, Australia.
Article Synopsis
- The review highlights key advancements in 2023 regarding Interstitial Lung Disease (ILD), emphasizing the link between pollution and genetic factors that heighten the risk of Idiopathic Pulmonary Fibrosis (IPF).
- It points out that malnutrition, as a comorbidity, has not been fully acknowledged in ILD cases.
- The study also mentions novel genes related to IPF, signaling pathways influencing lung remodeling, new methods for disease monitoring, and innovative treatments like inhaled pirfenidone and efzofitimod for sarcoidosis.
Genetic association of lipids and lipid lowering drug target genes with sarcoidosis.
Sci Rep
October 2024
Department of Pulmonology, Affiliated Hospital of Hunan Academy of Traditional Chinese Medicine, Changsha, China.
Article Synopsis
- * The analysis indicated a positive association between higher levels of LDL-c and TG and increased risk of sarcoidosis, with significant odds ratios supporting this finding.
- * Additionally, drug target randomization suggested that lowering LDL-c via PCSK9 inhibitors and reducing TG levels through LPL-targeted drugs could potentially decrease the risk of developing sarcoidosis.
Extrapulmonary sarcoidosis.
J Autoimmun
December 2024
Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Article Synopsis
- - Sarcoidosis is a chronic inflammatory disease that arises in genetically susceptible individuals after exposure to certain antigens, primarily affecting the lungs but potentially impacting any organ, including the heart, nervous system, and eyes, which can lead to severe complications.
- - Diagnosis is typically easier when typical symptoms and biopsy findings are present, but it becomes more complex when symptoms manifest in areas outside the lungs without accompanying lung issues.
- - First-line treatment for sarcoidosis involves corticosteroids, while immunosuppressive or biologic medications are used for patients who do not respond to steroids or have refractory disease.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!